Literature DB >> 22624715

DNA methylation screening identifies driver epigenetic events of cancer cell survival.

Daniel D De Carvalho1, Shikhar Sharma2, Jueng Soo You1, Sheng-Fang Su2, Phillippa C Taberlay1, Theresa K Kelly1, Xiaojing Yang1, Gangning Liang1, Peter A Jones3.   

Abstract

Cancer cells typically exhibit aberrant DNA methylation patterns that can drive malignant transformation. Whether cancer cells are dependent on these abnormal epigenetic modifications remains elusive. We used experimental and bioinformatic approaches to unveil genomic regions that require DNA methylation for survival of cancer cells. First, we surveyed the residual DNA methylation profiles in cancer cells with highly impaired DNA methyltransferases. Then, we clustered these profiles according to their DNA methylation status in primary normal and tumor tissues. Finally, we used gene expression meta-analysis to identify regions that are dependent on DNA methylation-mediated gene silencing. We further showed experimentally that these genes must be silenced by DNA methylation for cancer cell survival, suggesting these are key epigenetic events associated with tumorigenesis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22624715      PMCID: PMC3395886          DOI: 10.1016/j.ccr.2012.03.045

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  60 in total

1.  IRAK-M is a negative regulator of Toll-like receptor signaling.

Authors:  Koichi Kobayashi; Lorraine D Hernandez; Jorge E Galán; Charles A Janeway; Ruslan Medzhitov; Richard A Flavell
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

2.  Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer.

Authors:  Marcos R H Estécio; Juan Gallegos; Céline Vallot; Ryan J Castoro; Woonbok Chung; Shinji Maegawa; Yasuhiro Oki; Yutaka Kondo; Jaroslav Jelinek; Lanlan Shen; Helge Hartung; Peter D Aplan; Bogdan A Czerniak; Shoudan Liang; Jean-Pierre J Issa
Journal:  Genome Res       Date:  2010-08-17       Impact factor: 9.043

3.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

Review 4.  DNA methylation and human disease.

Authors:  Keith D Robertson
Journal:  Nat Rev Genet       Date:  2005-08       Impact factor: 53.242

5.  Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line.

Authors:  Einav Nili Gal-Yam; Gerda Egger; Leo Iniguez; Heather Holster; Steingrímur Einarsson; Xinmin Zhang; Joy C Lin; Gangning Liang; Peter A Jones; Amos Tanay
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-27       Impact factor: 11.205

6.  Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival.

Authors:  Gerda Egger; Shinwu Jeong; Sonia G Escobar; Connie C Cortez; Tony W H Li; Yoshimasa Saito; Christine B Yoo; Peter A Jones; Gangning Liang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-08       Impact factor: 11.205

7.  Non-oncogene addiction and the stress phenotype of cancer cells.

Authors:  Nicole L Solimini; Ji Luo; Stephen J Elledge
Journal:  Cell       Date:  2007-09-21       Impact factor: 41.582

Review 8.  Epigenetic modifications as therapeutic targets.

Authors:  Theresa K Kelly; Daniel D De Carvalho; Peter A Jones
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

9.  Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance.

Authors:  Shikhar Sharma; Daniel D De Carvalho; Shinwu Jeong; Peter A Jones; Gangning Liang
Journal:  PLoS Genet       Date:  2011-02-03       Impact factor: 5.917

10.  Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme.

Authors:  Li-Jen Su; Ching-Wei Chang; Yu-Chung Wu; Kuang-Chi Chen; Chien-Ju Lin; Shu-Ching Liang; Chi-Hung Lin; Jacqueline Whang-Peng; Shih-Lan Hsu; Chen-Hsin Chen; Chi-Ying F Huang
Journal:  BMC Genomics       Date:  2007-06-01       Impact factor: 3.969

View more
  111 in total

1.  Epigenetics. Dissecting driving DNA methylations.

Authors:  Darren J Burgess
Journal:  Nat Rev Cancer       Date:  2012-06-07       Impact factor: 60.716

2.  DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.

Authors:  David Roulois; Helen Loo Yau; Rajat Singhania; Yadong Wang; Arnavaz Danesh; Shu Yi Shen; Han Han; Gangning Liang; Peter A Jones; Trevor J Pugh; Catherine O'Brien; Daniel D De Carvalho
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

3.  The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease.

Authors:  Shan He; Fang Xie; Yongnian Liu; Qing Tong; Kazuhiro Mochizuki; Philip E Lapinski; Ram-Shankar Mani; Pavan Reddy; Izumi Mochizuki; Arul M Chinnaiyan; Shin Mineishi; Philip D King; Yi Zhang
Journal:  Blood       Date:  2013-10-18       Impact factor: 22.113

4.  Epigenetic regulation of the novel tumor suppressor cysteine dioxygenase 1 in esophageal squamous cell carcinoma.

Authors:  Junhye Kwon; Misun Park; Ji-Hee Kim; Hae Won Lee; Moon Chul Kang; Jong Ho Park
Journal:  Tumour Biol       Date:  2015-04-24

Review 5.  DNA methylation dynamics in health and disease.

Authors:  Yehudit Bergman; Howard Cedar
Journal:  Nat Struct Mol Biol       Date:  2013-03       Impact factor: 15.369

Review 6.  Interplay between the cancer genome and epigenome.

Authors:  Hui Shen; Peter W Laird
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

Review 7.  The future of epigenetic therapy in solid tumours--lessons from the past.

Authors:  Nilofer Azad; Cynthia A Zahnow; Charles M Rudin; Stephen B Baylin
Journal:  Nat Rev Clin Oncol       Date:  2013-04-02       Impact factor: 66.675

8.  Identification of DNA Methylation-Independent Epigenetic Events Underlying Clear Cell Renal Cell Carcinoma.

Authors:  Elinne Becket; Sameer Chopra; Christopher E Duymich; Justin J Lin; Jueng Soo You; Kurinji Pandiyan; Peter W Nichols; Kimberly D Siegmund; Jessica Charlet; Daniel J Weisenberger; Peter A Jones; Gangning Liang
Journal:  Cancer Res       Date:  2016-01-12       Impact factor: 12.701

9.  Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer.

Authors:  Mark O Kitchen; Richard T Bryan; Richard D Emes; John R Glossop; Christopher Luscombe; K K Cheng; Maurice P Zeegers; Nicholas D James; Adam J Devall; Charles A Mein; Lyndon Gommersall; Anthony A Fryer; William E Farrell
Journal:  Epigenetics       Date:  2016-03-01       Impact factor: 4.528

10.  Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression.

Authors:  Gamze Kuser-Abali; Ahmet Alptekin; Bekir Cinar
Journal:  Epigenetics       Date:  2014-02-27       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.